Abraham A S, Balkin J, Rosenmann D, Ilan M, Klutstein M, Zion M M
Department of Internal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Magnes Res. 1994 Dec;7(3-4):273-6.
Ninety-five patients with acute myocardial infarction were followed up for 6 months to 3 years (mean 25.4 months) in a preliminary study to compare the effects of intravenous magnesium (49 patients) with that of intravenous propranolol (44 patients) given immediately after admission to the intensive care unit. There were four cardiac deaths in the propranolol group and no deaths in the magnesium group (P < 0.046) and 27 per cent of patients who received propranolol subsequently developed cardiac failure as opposed to 12 per cent of those who had received magnesium (P < 0.04). Intravenous magnesium given in the early stages of myocardial infarction reduces the subsequent cardiac death rate possibly by reducing infarct size.
在一项初步研究中，对95例急性心肌梗死患者进行了6个月至3年的随访（平均25.4个月），以比较在重症监护病房入院后立即静脉注射镁（49例患者）与静脉注射普萘洛尔（44例患者）的效果。普萘洛尔组有4例心源性死亡，镁组无死亡（P<0.046），接受普萘洛尔治疗的患者中有27%随后发生心力衰竭，而接受镁治疗的患者中这一比例为12%（P<0.04）。在心肌梗死早期静脉注射镁可能通过缩小梗死面积降低随后的心源性死亡率。
